Advanced
Clinical
Pharmacother
apeutics in
Anesthesiolog
y: 2026/2027
Elite
Competency
,Test Bank
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Questions 1–15: Foundational Syntax & Application: Pharmacokinetics,
receptor theory, and 2026 FDA approvals (NaV1.8 inhibitors, GLP-1 guidelines,
SGLT2i parameters).
○ Questions 16–40: Professional Simulation: Crisis resource management (LAST,
MH), TCI integration, procedure-specific fascial plane blocks, and acute
perioperative interventions.
○ Questions 41–66: Grandmaster Synthesis: Multi-system crises, legal/ethical
delegation (Texas APRN standards), and complex receptor interplay requiring
high-level algorithmic execution.
PART I: THE PRIMER
Mastering the precise pharmacodynamics of modern anesthesiology separates elite clinicians
from mere technicians; your intuition is the final barrier between optimal recovery and
catastrophic physiological collapse. You do not just administer drugs; you orchestrate complex,
high-stakes molecular cascades in real-time.
● LAST Protocol (2026): 20% Intralipid. Bolus 1.5 mL/kg. Infusion 0.25 mL/kg/min. Max
dose 12 mL/kg. Avoid vasopressin, beta-blockers, and calcium channel blockers.
Epinephrine must be < 1 mcg/kg.
● Malignant Hyperthermia: Ryanodex 2.5 mg/kg push (reconstitutes in 5 mL sterile water,
< 1 min).
● GLP-1 Agonists: Hold daily doses on the day of surgery; hold weekly doses 1 week prior.
Use Gastric POCUS if fasting status is questionable.
● SGLT2 Inhibitors: Hold 3-4 days pre-op to avert euglycemic diabetic ketoacidosis
(eDKA).
● Buprenorphine: Continue home dose perioperatively; do not mandate a preoperative
taper.
PART II: THE ELITE TEST BANK
Q1: A 55-year-old patient taking ertugliflozin (an SGLT2 inhibitor) presents for an elective total
knee arthroplasty. According to 2026 FDA and ASA consensus guidelines, what is the
REQUIRED preoperative holding parameter for this specific medication? A) Hold 24 hours prior
to surgery. B) Hold 3 days prior to surgery. C) Hold 4 days prior to surgery. D) Continue the
, medication through the day of surgery to maintain glycemic control.
● The Answer: C (Hold 4 days prior to surgery.)
● Distractor Analysis:
○ A is incorrect: This is the standard for older oral hypoglycemics like metformin or
sulfonylureas.
○ B is incorrect: While most SGLT2 inhibitors require a 3-day hold, ertugliflozin
specifically requires a 4-day hold due to its longer half-life. * D is incorrect:
Continuing SGLT2 inhibitors perioperatively drastically increases the risk of
euglycemic diabetic ketoacidosis (eDKA) during surgical stress.
The Mentor's Analysis: SGLT2 inhibitors induce a unique metabolic
vulnerability—eDKA—because they artificially lower blood glucose without suppressing
ketogenesis. During surgical fasting, the body enters a starvation state, driving massive ketone
production while serum glucose remains deceptively normal. Professional Intuition: Treat
ertugliflozin as the outlier of its class; always mandate a 96-hour washout.
Q2: The 2026 American Society of Anesthesiologists (ASA) guidelines for perioperative pain
management strongly advocate for the use of fascial plane blocks. Which of the following is the
PRIMARY targeted outcome of this regional technique in open abdominal surgery? A) Complete
surgical anesthesia without the need for volatile agents. B) Reduction of pain and oral morphine
equivalents (OME) in the first 24 hours postoperatively. C) Immediate reversal of neuromuscular
blockade. D) Prevention of local anesthetic systemic toxicity (LAST).
● The Answer: B (Reduction of pain and oral morphine equivalents (OME) in the first 24
hours postoperatively.)
● Distractor Analysis:
○ A is incorrect: Fascial plane blocks are analgesic adjuncts, not complete surgical
anesthetics for intra-abdominal visceral stimulation.
○ C is incorrect: Regional anesthesia has no pharmacological effect on the
neuromuscular junction.
○ D is incorrect: Fascial plane blocks require high volumes of local anesthetic, which
actually increases the risk of LAST if not executed with precise ultrasound
guidance.
The Mentor's Analysis: Fascial plane blocks bathe nerve networks in potential spaces. They
are the cornerstone of the modern Opioid-Free/Opioid-Sparing Anesthesia (OFA) matrix.
Professional Intuition: Frame these blocks to your surgeons not as an alternative to general
anesthesia, but as a preemptive strike against the 24-hour postoperative opioid cascade.
Q3: Suzetrigine (Journavx) was approved by the FDA as a novel non-opioid analgesic. What is
the EXACT molecular mechanism of action for this agent? A) It is a competitive antagonist at
the mu-opioid receptor. B) It selectively inhibits NaV1.8 voltage-gated sodium channels in
peripheral sensory neurons. C) It is a highly selective alpha-2 adrenergic agonist. D) It acts as a
non-competitive NMDA receptor antagonist.
● The Answer: B (It selectively inhibits NaV1.8 voltage-gated sodium channels in
peripheral sensory neurons.)
● Distractor Analysis:
○ A is incorrect: This describes naloxone or naltrexone.
○ C is incorrect: This describes dexmedetomidine or clonidine.
○ D is incorrect: This describes ketamine.
The Mentor's Analysis: Suzetrigine represents a paradigm shift. By selectively targeting the
NaV1.8 channel located purely in the dorsal root ganglion (DRG) nociceptive C-fibers, it halts
pain signal propagation before it reaches the CNS. It provides opioid-level analgesia without
Clinical
Pharmacother
apeutics in
Anesthesiolog
y: 2026/2027
Elite
Competency
,Test Bank
PART 0: THE NAVIGATOR
● PART I: THE PRIMER
○ The "Welcome to the Big Leagues" Hook
○ The "Panic Button" Cheat Sheet
● PART II: THE ELITE TEST BANK
○ Questions 1–15: Foundational Syntax & Application: Pharmacokinetics,
receptor theory, and 2026 FDA approvals (NaV1.8 inhibitors, GLP-1 guidelines,
SGLT2i parameters).
○ Questions 16–40: Professional Simulation: Crisis resource management (LAST,
MH), TCI integration, procedure-specific fascial plane blocks, and acute
perioperative interventions.
○ Questions 41–66: Grandmaster Synthesis: Multi-system crises, legal/ethical
delegation (Texas APRN standards), and complex receptor interplay requiring
high-level algorithmic execution.
PART I: THE PRIMER
Mastering the precise pharmacodynamics of modern anesthesiology separates elite clinicians
from mere technicians; your intuition is the final barrier between optimal recovery and
catastrophic physiological collapse. You do not just administer drugs; you orchestrate complex,
high-stakes molecular cascades in real-time.
● LAST Protocol (2026): 20% Intralipid. Bolus 1.5 mL/kg. Infusion 0.25 mL/kg/min. Max
dose 12 mL/kg. Avoid vasopressin, beta-blockers, and calcium channel blockers.
Epinephrine must be < 1 mcg/kg.
● Malignant Hyperthermia: Ryanodex 2.5 mg/kg push (reconstitutes in 5 mL sterile water,
< 1 min).
● GLP-1 Agonists: Hold daily doses on the day of surgery; hold weekly doses 1 week prior.
Use Gastric POCUS if fasting status is questionable.
● SGLT2 Inhibitors: Hold 3-4 days pre-op to avert euglycemic diabetic ketoacidosis
(eDKA).
● Buprenorphine: Continue home dose perioperatively; do not mandate a preoperative
taper.
PART II: THE ELITE TEST BANK
Q1: A 55-year-old patient taking ertugliflozin (an SGLT2 inhibitor) presents for an elective total
knee arthroplasty. According to 2026 FDA and ASA consensus guidelines, what is the
REQUIRED preoperative holding parameter for this specific medication? A) Hold 24 hours prior
to surgery. B) Hold 3 days prior to surgery. C) Hold 4 days prior to surgery. D) Continue the
, medication through the day of surgery to maintain glycemic control.
● The Answer: C (Hold 4 days prior to surgery.)
● Distractor Analysis:
○ A is incorrect: This is the standard for older oral hypoglycemics like metformin or
sulfonylureas.
○ B is incorrect: While most SGLT2 inhibitors require a 3-day hold, ertugliflozin
specifically requires a 4-day hold due to its longer half-life. * D is incorrect:
Continuing SGLT2 inhibitors perioperatively drastically increases the risk of
euglycemic diabetic ketoacidosis (eDKA) during surgical stress.
The Mentor's Analysis: SGLT2 inhibitors induce a unique metabolic
vulnerability—eDKA—because they artificially lower blood glucose without suppressing
ketogenesis. During surgical fasting, the body enters a starvation state, driving massive ketone
production while serum glucose remains deceptively normal. Professional Intuition: Treat
ertugliflozin as the outlier of its class; always mandate a 96-hour washout.
Q2: The 2026 American Society of Anesthesiologists (ASA) guidelines for perioperative pain
management strongly advocate for the use of fascial plane blocks. Which of the following is the
PRIMARY targeted outcome of this regional technique in open abdominal surgery? A) Complete
surgical anesthesia without the need for volatile agents. B) Reduction of pain and oral morphine
equivalents (OME) in the first 24 hours postoperatively. C) Immediate reversal of neuromuscular
blockade. D) Prevention of local anesthetic systemic toxicity (LAST).
● The Answer: B (Reduction of pain and oral morphine equivalents (OME) in the first 24
hours postoperatively.)
● Distractor Analysis:
○ A is incorrect: Fascial plane blocks are analgesic adjuncts, not complete surgical
anesthetics for intra-abdominal visceral stimulation.
○ C is incorrect: Regional anesthesia has no pharmacological effect on the
neuromuscular junction.
○ D is incorrect: Fascial plane blocks require high volumes of local anesthetic, which
actually increases the risk of LAST if not executed with precise ultrasound
guidance.
The Mentor's Analysis: Fascial plane blocks bathe nerve networks in potential spaces. They
are the cornerstone of the modern Opioid-Free/Opioid-Sparing Anesthesia (OFA) matrix.
Professional Intuition: Frame these blocks to your surgeons not as an alternative to general
anesthesia, but as a preemptive strike against the 24-hour postoperative opioid cascade.
Q3: Suzetrigine (Journavx) was approved by the FDA as a novel non-opioid analgesic. What is
the EXACT molecular mechanism of action for this agent? A) It is a competitive antagonist at
the mu-opioid receptor. B) It selectively inhibits NaV1.8 voltage-gated sodium channels in
peripheral sensory neurons. C) It is a highly selective alpha-2 adrenergic agonist. D) It acts as a
non-competitive NMDA receptor antagonist.
● The Answer: B (It selectively inhibits NaV1.8 voltage-gated sodium channels in
peripheral sensory neurons.)
● Distractor Analysis:
○ A is incorrect: This describes naloxone or naltrexone.
○ C is incorrect: This describes dexmedetomidine or clonidine.
○ D is incorrect: This describes ketamine.
The Mentor's Analysis: Suzetrigine represents a paradigm shift. By selectively targeting the
NaV1.8 channel located purely in the dorsal root ganglion (DRG) nociceptive C-fibers, it halts
pain signal propagation before it reaches the CNS. It provides opioid-level analgesia without
